Biomaterial Database

Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats. 2006

David Loch, and Scott Levick, and Andrew Hoey, and Lindsay Brown

Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, Australia.

The pleiotropic effects of statins represent potential mechanisms for the treatment of end-organ damage in hypertension. This study has investigated the effects of rosuvastatin in a model of cardiovascular remodeling, the DOCA-salt hypertensive rat. Male Wistar rats weighing 300 to 330 g were uninephrectomized (UNX) or UNX and treated with DOCA (25 mg subcutaneously every fourth day) and 1% NaCl in the drinking water. Compared with UNX controls, DOCA-salt rats developed hypertension, cardiovascular hypertrophy, inflammation with perivascular and interstitial cardiac fibrosis, endothelial dysfunction, and prolongation of ventricular action potential duration at 28 days. Rosuvastatin-treated rats received 20 mg/kg/d of the drug in 10% Tween 20 by oral gavage for 32 days commencing 4 days before uninephrectomy. UNX and DOCA-salt controls received vehicle only. Rosuvastatin therapy attenuated the development of cardiovascular hypertrophy, inflammation, fibrosis, and ventricular action potential prolongation, but did not modify hypertension or vascular dysfunction. We conclude that the pleiotropic effects of rosuvastatin include attenuation of aspects of cardiovascular remodeling in the DOCA-salt model of hypertension in rats without altering systolic blood pressure.

UI	MeSH Term	Description	Entries
D006973	Hypertension	Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D006984	Hypertrophy	General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	Hypertrophies
D008297	Male		Males
D009206	Myocardium	The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow.	Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D011743	Pyrimidines	A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D001794	Blood Pressure	PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.	Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003900	Desoxycorticosterone	A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE	21-Hydroxyprogesterone,Cortexone,Deoxycorticosterone,Desoxycortone,11-Decorticosterone,21-Hydroxy-4-pregnene-3,20-dione,11 Decorticosterone,21 Hydroxy 4 pregnene 3,20 dione,21 Hydroxyprogesterone
D005355	Fibrosis	Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	Cirrhosis,Fibroses
D005464	Fluorobenzenes	Derivatives of BENZENE that contain FLUORINE.	Fluorobenzene
D000068718	Rosuvastatin Calcium	A HYDROXYMETHYLGLUTARYL-COA-REDUCTASE INHIBITOR, or statin, that reduces the plasma concentrations of LDL-CHOLESTEROL; APOLIPOPROTEIN B, and TRIGLYCERIDES while increasing HDL-CHOLESTEROL levels in patients with HYPERCHOLESTEROLEMIA and those at risk for CARDIOVASCULAR DISEASES.	Crestor,Rosuvastatin,ZD 4522,ZD4522,Calcium, Rosuvastatin

Related Publications

David Loch, and Scott Levick, and Andrew Hoey, and Lindsay Brown

l-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats.

October 2005, American journal of physiology. Heart and circulatory physiology,

David Loch, and Scott Levick, and Andrew Hoey, and Lindsay Brown

Naloxone attenuates development of hypertension in DOCA-salt hypertensive rats.

January 1991, Clinical and experimental hypertension. Part A, Theory and practice,

David Loch, and Scott Levick, and Andrew Hoey, and Lindsay Brown

Renoprotective effect of rosuvastatin in DOCA-salt hypertensive rats.

April 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,

David Loch, and Scott Levick, and Andrew Hoey, and Lindsay Brown

Impaired flow-induced arterial remodeling in DOCA-salt hypertensive rats.

November 2012, Hypertension research : official journal of the Japanese Society of Hypertension,

David Loch, and Scott Levick, and Andrew Hoey, and Lindsay Brown

DOCA-salt induced malignant hypertension in spontaneously hypertensive rats.

February 1984, Journal of hypertension,

David Loch, and Scott Levick, and Andrew Hoey, and Lindsay Brown

Humoral factors and blood pressure in DOCA-salt hypertensive rats.

July 1997, American journal of hypertension,

David Loch, and Scott Levick, and Andrew Hoey, and Lindsay Brown

Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats.

January 2013, Clinical and experimental hypertension (New York, N.Y. : 1993),